{"id":"W2403393996","doi":"10.1158/1538-7445.sabcs15-s5-07","title":"Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Breast cancer; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progressive disease; Immunotherapy; Clinical trial; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001055505,0.000581224,0.0008730444,0.0002228889,0.0003381669,0.0007163692,0.0003959481,0.0007825102,0.008916228],"category_scores_gemma":[0.001125949,0.000222269,0.0009873252,0.00025454,0.0003825081,0.0006445008,0.0003019995,0.001841698,0.001353904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008251207,"about_ca_system_score_gemma":0.001209939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005898772,"about_ca_topic_score_gemma":0.001014568,"domain_scores_codex":[0.9996889,0.0001169137,0.00003139564,0.00006317512,0.00004902566,0.00005077087],"domain_scores_gemma":[0.9993147,0.0001271078,0.0001329908,0.00005342872,0.00008953954,0.0002823015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7138698,0.0302048,0.03140139,0.001222723,0.001613866,0.0005043914,0.0002467546,0.002022549,0.06461286,0.00032107,0.0168442,0.1371357],"study_design_scores_gemma":[0.2742816,0.5612037,0.1205456,0.0001792947,0.002218047,0.001020856,0.0001690904,0.004273394,0.02223271,0.0004742773,0.01332881,0.00007259419],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869798,0.001272616,0.0005938443,0.0004336891,0.00008229366,0.00136182,0.005926556,0.0001159781,0.003233361],"genre_scores_gemma":[0.9887734,0.0003770817,0.0008619525,0.0006297597,0.00008554394,0.0007386106,0.006993891,0.00001958765,0.001520186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008916228,"threshold_uncertainty_score":0.02982777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01529012457989496,"score_gpt":0.3262191982827851,"score_spread":0.3109290737028901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}